Eiger BioPharmaceuticals, Inc.;The Board of Trustees of the Leland Stanford Junior University
发明人:
Xiaofeng Xiong,Debra Odink,Colleen M. Craig,Christine M.N. Smith
申请号：
US16461329
公开号：
US20200069802A1
申请日:
2017.11.21
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.
